Abhijeet Ojha
Abhijeet Ojha has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Arun Kumar Singh
Faculty of Pharmaceutical Sciences, Amrapali University, Haldwani, Uttarakhand, India
5 shared publications - Vikas Bhatt
Faculty of Pharmaceutical Sciences (FPS), Amrapali University (Haldwani), India
3 shared publications Akhter
Faculty of Pharmacy, DIT University, Dehradun, Uttarakhand, India
1 shared publicationAnuj Nautiyal
Faculty of Pharmacy, DIT University, Dehradun, Uttarakhand, India
1 shared publication- Harish Chandra
Department of Botany and Microbiology, Gurukula Kangri (Deemed to be University), Haridwar, India
1 shared publication - Karuna Dhaundhiyal
Faculty of Pharmaceutical Sciences (FPS), Amrapali University (Haldwani), India
1 shared publication
Latest Publications
- Open Access
- 15 September 2026
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 16 (9) , 350-356
Nanocarrier Platforms in Cancer Therapeutics: Design, Advances and Clinical Translation Challenges
Nanotechnology has emerged as a transformative frontier for detecting and treating various types of tumours more accurately. As a leading technology, nanotechnology assists in overcoming the issues linked with traditional antitumor drug systems. Nanocarriers (NCs) are colloidal systems developed for precise drug delivery; their main objective is to surpass the protective and efficient barriers. Nanocarriers have been widely studied over the last few decades as they are highly helpful and play an important role in drug delivery across different fields. They show better performance compared to other methods by overcoming the limitations related to low targeting ability, damage to healthy cells, toxicity, and immediate drug release. To achieve this goal, novel NCs like microemulsions, vesicular (liposomes), and nanoparticular NCs are created and explored. These new NCs have unique improved penetration and retention in the tumour tissue. Nano-therapy has advanced the delivery of chemotherapeutic medicines in cancer. Additionally, their uses in many other therapeutic areas have been remarkable, and there is yet much more to be discovered to facilitate their successful clinical translation. Keywords: Nanotechnology, Nanocarriers, Targeted therapy, Cancer therapeutics
- 15 September 2026
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 16 (9) , 350-356
Open AccessNanocarrier Platforms in Cancer Therapeutics: Design, Advances and Clinical Translation Challenges
Nanotechnology has emerged as a transformative frontier for detecting and treating various types of tumours more accurately. As a leading technology, nanotechnology assists in overcoming the issues linked with traditional antitumor drug systems. Nanocarriers (NCs) are colloidal systems developed for precise drug delivery; their main objective is to surpass the protective and efficient barriers. Nanocarriers have been widely studied over the last few decades as they are highly helpful and play an important role in drug delivery across different fields. They show better performance compared to other methods by overcoming the limitations related to low targeting ability, damage to healthy cells, toxicity, and immediate drug release. To achieve this goal, novel NCs like microemulsions, vesicular (liposomes), and nanoparticular NCs are created and explored. These new NCs have unique improved penetration and retention in the tumour tissue. Nano-therapy has advanced the delivery of chemotherapeutic medicines in cancer. Additionally, their uses in many other therapeutic areas have been remarkable, and there is yet much more to be discovered to facilitate their successful clinical translation. Keywords: Nanotechnology, Nanocarriers, Targeted therapy, Cancer therapeutics
- Open Access
- 15 July 2026
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 16 (7) , 182-189
Emerging Trends in Effervescent Granules: From Conventional Formulation to Novel Drug Delivery System: A Review
Purpose: Widely used pharmaceutical dosages form are effervescent granules designed to improve bioavailability, drug dissolution and improve the patient compliance. This review provide a brief overview of modern formulation approaches and highlights the recent improvement in effervescent granules based delivery. Effervescent granule a widely used pharmaceutical dosages form designed to improve bioavailability, drug dissolution and improve patient compliance. This review provide a comprehensive overview of conventional formulation approaches and highlights the recent advantages in effervescent granule based delivery system. Methods: A comprehensive review of published literature, including research articles, review paper, and pharmaceutical text, was conducted. The collected data were analysed with respect of formulation principles, evaluation parameter, and recent technological advancement in effervescent systems. Results: Effervescent granules work on the function of acid base reaction that generates carbon dioxide when it come in contact with the water result in rapid disintegration and enhanced drug dissolution. This system offers rapid onset of action, enhanced palatability and better patient compliance. Recent innovation include control-release formulation, gastro retentive floating system, nanotechnology-based approaches and 3D printing techniques, have substantially expanded pharmaceutical application and therapeutic prospect. Conclusion: Effervescent granule portray a versatile and developing drug delivery system that bridges conventional formulation with modern pharmaceutical approach. Continuous advancement are expected to further improve their stability, efficacy and role in patient centric and personalized drug delivery system. Keywords: Effervescent granules, drug delivery system, bioavailability, formulation, control release, emerging trends
- 15 July 2026
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 16 (7) , 182-189
Open AccessEmerging Trends in Effervescent Granules: From Conventional Formulation to Novel Drug Delivery System: A Review
Purpose: Widely used pharmaceutical dosages form are effervescent granules designed to improve bioavailability, drug dissolution and improve the patient compliance. This review provide a brief overview of modern formulation approaches and highlights the recent improvement in effervescent granules based delivery. Effervescent granule a widely used pharmaceutical dosages form designed to improve bioavailability, drug dissolution and improve patient compliance. This review provide a comprehensive overview of conventional formulation approaches and highlights the recent advantages in effervescent granule based delivery system. Methods: A comprehensive review of published literature, including research articles, review paper, and pharmaceutical text, was conducted. The collected data were analysed with respect of formulation principles, evaluation parameter, and recent technological advancement in effervescent systems. Results: Effervescent granules work on the function of acid base reaction that generates carbon dioxide when it come in contact with the water result in rapid disintegration and enhanced drug dissolution. This system offers rapid onset of action, enhanced palatability and better patient compliance. Recent innovation include control-release formulation, gastro retentive floating system, nanotechnology-based approaches and 3D printing techniques, have substantially expanded pharmaceutical application and therapeutic prospect. Conclusion: Effervescent granule portray a versatile and developing drug delivery system that bridges conventional formulation with modern pharmaceutical approach. Continuous advancement are expected to further improve their stability, efficacy and role in patient centric and personalized drug delivery system. Keywords: Effervescent granules, drug delivery system, bioavailability, formulation, control release, emerging trends
- Open Access
- 15 June 2026
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 16 (6) , 263-271
Ethics of AI in Patient Recruitment and Diversity
By 2026, global clinical research has seen a shift from voluntary diversity programs to mandatory regulation. This report examines the ethical and technical issues at the interface of artificial intelligence (AI) and demographic representation in trial enrollment. In the U.S. under the Food and Drug Administration's Diversity Action Plans and in India's New Drugs and Clinical Trials (NDCT) Rules of 2026, sponsors must now demonstrate that trial groups reflect the real-world diversity of the intended patient population.1, 2, 3 AI tools like TrialGPT and DocTr have emerged as key solutions, reporting up to 98.7% reduction in screening time and a 58% improvement in matching quality through analysis of large electronic health record (EHR) datasets.4, 5, 6 However, these technologies introduce significant ethical concerns, including "black box" epistemic opacity and algorithmic bias that can institutionalize healthcare inequalities.7, 8, 17 A persistent digital divide also excludes groups that lack high-speed connectivity or digital literacy.9, 10 This paper argues that although AI is central to achieving large-scale diversity in clinical research results, it must be implemented within governance frameworks such as the EU AI Act and WHO ethical guidelines, which guarantee human oversight, transparency, and data justice.10, 11, 12, 13 We recommend adherence to PRISMA 2020 reporting standards to ensure methodological rigor in the evaluation of AI-based recruitment interventions.12, 14 Keywords: Ethics, Clinical Trials, Patient Recruitment, Diversity, Artificial Intelligence, Bioethical
- 15 June 2026
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 16 (6) , 263-271
Open AccessEthics of AI in Patient Recruitment and Diversity
By 2026, global clinical research has seen a shift from voluntary diversity programs to mandatory regulation. This report examines the ethical and technical issues at the interface of artificial intelligence (AI) and demographic representation in trial enrollment. In the U.S. under the Food and Drug Administration's Diversity Action Plans and in India's New Drugs and Clinical Trials (NDCT) Rules of 2026, sponsors must now demonstrate that trial groups reflect the real-world diversity of the intended patient population.1, 2, 3 AI tools like TrialGPT and DocTr have emerged as key solutions, reporting up to 98.7% reduction in screening time and a 58% improvement in matching quality through analysis of large electronic health record (EHR) datasets.4, 5, 6 However, these technologies introduce significant ethical concerns, including "black box" epistemic opacity and algorithmic bias that can institutionalize healthcare inequalities.7, 8, 17 A persistent digital divide also excludes groups that lack high-speed connectivity or digital literacy.9, 10 This paper argues that although AI is central to achieving large-scale diversity in clinical research results, it must be implemented within governance frameworks such as the EU AI Act and WHO ethical guidelines, which guarantee human oversight, transparency, and data justice.10, 11, 12, 13 We recommend adherence to PRISMA 2020 reporting standards to ensure methodological rigor in the evaluation of AI-based recruitment interventions.12, 14 Keywords: Ethics, Clinical Trials, Patient Recruitment, Diversity, Artificial Intelligence, Bioethical
- Open Access
- 15 April 2026
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 16 (4) , 185-194
Nanotechnology-Driven Drug Delivery System: Recent Advances, Applications and Future Perspectives
Purpose: With the ability to solve problems of standard medicine, nanotechnology is presently an innovative technology in advanced pharmaceutical delivery. A wide range of nanocarriers, including lipid-based systems, polymeric nanoparticles, self-assembled structures, and functionalized nanomaterials, provides diverse platforms for the delivery of a range of medicaments, extending from pure substances to genetic therapies like siRNA 4. Methods: This review highlights the application of nanotechnology-based systems in drug delivery, including their role in tumour research, bronchial delivery, oral therapeutic formulations, and even integrated techniques such as diagnostic-guided therapy, which blends the assessment and cure. Results: By presenting the accurate transfer and managed release, nanoparticles can strengthen the therapeutic solubility, durability, and uptake while facilitating the therapeutic results and minimizing the side effects2,3.An additional benchmark has been given to Antitumor therapy, where site-specific nanoparticles and reaction-prone system reduce the harm to nourishing cells while strengthening the treatment reproducibility3,8. Green and sustainable nanomaterials focus on the advancement towards reliable, planet-friendly, and user-friendly formulations5. Conclusion: Regardless of these new methods, hardships remain in assuring large-batch production, prolonged safety, loss prevention, and sandardization approval6. Currently, investigation prevails to more evident technological approaches, plan efficient carriers, and analyse future opportunities where nano-drug delivery could alter the healthcare on an international scale7 . Keywords: nanocarriers, bioavailability, diagnostic-guided therapy, targeted delivery, novel drug delivery system.
- 15 April 2026
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 16 (4) , 185-194
Open AccessNanotechnology-Driven Drug Delivery System: Recent Advances, Applications and Future Perspectives
Purpose: With the ability to solve problems of standard medicine, nanotechnology is presently an innovative technology in advanced pharmaceutical delivery. A wide range of nanocarriers, including lipid-based systems, polymeric nanoparticles, self-assembled structures, and functionalized nanomaterials, provides diverse platforms for the delivery of a range of medicaments, extending from pure substances to genetic therapies like siRNA 4. Methods: This review highlights the application of nanotechnology-based systems in drug delivery, including their role in tumour research, bronchial delivery, oral therapeutic formulations, and even integrated techniques such as diagnostic-guided therapy, which blends the assessment and cure. Results: By presenting the accurate transfer and managed release, nanoparticles can strengthen the therapeutic solubility, durability, and uptake while facilitating the therapeutic results and minimizing the side effects2,3.An additional benchmark has been given to Antitumor therapy, where site-specific nanoparticles and reaction-prone system reduce the harm to nourishing cells while strengthening the treatment reproducibility3,8. Green and sustainable nanomaterials focus on the advancement towards reliable, planet-friendly, and user-friendly formulations5. Conclusion: Regardless of these new methods, hardships remain in assuring large-batch production, prolonged safety, loss prevention, and sandardization approval6. Currently, investigation prevails to more evident technological approaches, plan efficient carriers, and analyse future opportunities where nano-drug delivery could alter the healthcare on an international scale7 . Keywords: nanocarriers, bioavailability, diagnostic-guided therapy, targeted delivery, novel drug delivery system.
- Open Access
- 1 August 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Pharmacy and Pharmaceutical Sciences
- p. 1-7
3D PRINTING IN PHARMACEUTICALS: TRANSFORMING DRUG FORMULATION AND PERSONALIZED MEDICINE
Three-dimensional printing is poised to transform the landscape of pharmaceutical manufacturing by enabling the tailored production of medicines that cater to individual patient requirements. Emphasizing its notable contributions to personalized medicine, this review explores the foundational principles and methods of 3D printing in drug delivery. Key methods, including Fused Deposition Modeling (FDM), Selective Laser Sintering (SLS), stereolithography (SLA), and semi-solid extrusion, are evaluated for their benefits and difficulties. The study shows how 3D printing overcomes the bounds of conventional manufacturing techniques, including one-size-fits-all and rigid dosing, thereby enabling the on-demand production of complex dosage forms with customized drug release properties and improved solubility for difficult compounds. Along with the historic FDA clearance of SPRITAM®, the first 3D-printed medicine, practical applications have been demonstrated in the production of pediatric mini-tablets, geriatric polypills, and multi-compartment capsules. Moreover, the study discusses how customized implantable devices, bioprinting, and 3D printing are progressively integrated. Although problems, including material compatibility, process standardization, and legal obstacles, still exist, the rapid development rate promises a future in which 3D printing is essential to pharmaceutical practice. It has great potential to enhance therapeutic results and patient quality of life substantially.
- 1 August 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Pharmacy and Pharmaceutical Sciences
- p. 1-7
Open Access3D PRINTING IN PHARMACEUTICALS: TRANSFORMING DRUG FORMULATION AND PERSONALIZED MEDICINE
Three-dimensional printing is poised to transform the landscape of pharmaceutical manufacturing by enabling the tailored production of medicines that cater to individual patient requirements. Emphasizing its notable contributions to personalized medicine, this review explores the foundational principles and methods of 3D printing in drug delivery. Key methods, including Fused Deposition Modeling (FDM), Selective Laser Sintering (SLS), stereolithography (SLA), and semi-solid extrusion, are evaluated for their benefits and difficulties. The study shows how 3D printing overcomes the bounds of conventional manufacturing techniques, including one-size-fits-all and rigid dosing, thereby enabling the on-demand production of complex dosage forms with customized drug release properties and improved solubility for difficult compounds. Along with the historic FDA clearance of SPRITAM®, the first 3D-printed medicine, practical applications have been demonstrated in the production of pediatric mini-tablets, geriatric polypills, and multi-compartment capsules. Moreover, the study discusses how customized implantable devices, bioprinting, and 3D printing are progressively integrated. Although problems, including material compatibility, process standardization, and legal obstacles, still exist, the rapid development rate promises a future in which 3D printing is essential to pharmaceutical practice. It has great potential to enhance therapeutic results and patient quality of life substantially.
- Open Access
- 22 February 2018
- Published by Sciencedomain International in Asian Journal of Medicine and Health
- Vol. 10 (2) , 1-7
The Prevalence, Risk Factors and Awareness of Hypertension in an Urban Population of Dehradun, Uttarakhand, India
To determine the prevalence and possible risk factors for prehypertension and hypertension state in Dehradun City of Uttarakhand (Northern India) using Joint National Committee (JNC) VII criteria, team of five pharmacy professional of DITUniversity -Faculty of Pharmacy were trained to measure blood pressure visited the localities randomly. The blood pressure (BP) of the participants was measured twice and the average value of the two measurements was considered. A total of 499 individuals (198 males and 301 females), responded aged ≥30 years in the survey. Overall prevalence of hypertension was 18.03%, (n = 90); 81(16.23%) had stage-I hypertension, 9 (1.80%) had stage-II hypertension. Only 228(45.69) subjects participated was found to have normal BP, while 181(36.27) were prehypertensive. In conclusion, the hypertension prevalent in the study population was low and prehypertension was found to be more in the population under study, and early intervention is necessary so that major health benefits can be given to the population that is possible through the implementation of primary prevention strategies and the risk of development of chronic kidney diseases and heart diseases could be prevented.
- 22 February 2018
- Published by Sciencedomain International in Asian Journal of Medicine and Health
- Vol. 10 (2) , 1-7
Open AccessThe Prevalence, Risk Factors and Awareness of Hypertension in an Urban Population of Dehradun, Uttarakhand, India
To determine the prevalence and possible risk factors for prehypertension and hypertension state in Dehradun City of Uttarakhand (Northern India) using Joint National Committee (JNC) VII criteria, team of five pharmacy professional of DITUniversity -Faculty of Pharmacy were trained to measure blood pressure visited the localities randomly. The blood pressure (BP) of the participants was measured twice and the average value of the two measurements was considered. A total of 499 individuals (198 males and 301 females), responded aged ≥30 years in the survey. Overall prevalence of hypertension was 18.03%, (n = 90); 81(16.23%) had stage-I hypertension, 9 (1.80%) had stage-II hypertension. Only 228(45.69) subjects participated was found to have normal BP, while 181(36.27) were prehypertensive. In conclusion, the hypertension prevalent in the study population was low and prehypertension was found to be more in the population under study, and early intervention is necessary so that major health benefits can be given to the population that is possible through the implementation of primary prevention strategies and the risk of development of chronic kidney diseases and heart diseases could be prevented.